|
| |
PRONOSTICS signs distribution agreement with MEDIPAN GmbH to sell its lead
products in Europe’s largest diagnostics market
Cambridge, UK, 12 March 2008 … Pronostics Ltd, developer and manufacturer of
next generation multiplexed diagnostics for healthcare providers and the
pharmaceutical industry, has signed a distribution agreement with Medipan GmbH,
for its autoimmune disease biomarker assays. This range of UltraPlex™ assays
provide a powerful tool for clinicians allowing for rapid, accurate and
inexpensive diagnosis of autoimmune diseases.
Medipan is a leader in the distribution of in vitro diagnostic tests in the
field of autoimmunity and will use its highly experienced sales force initially
to sell Pronostics’ UltraPlex™ ANA, Coeliac and Thyroid assays in Germany and
Austria. Germany is Europe’s largest market for diagnostic products. As part of
the agreement, Medipan will market the assays to hospitals and large private
laboratories. The deal could initially generate up to €2 million in revenues and
Medipan will have an exclusive license to sell the UltraPlex™ assays throughout
the territory. The 2005 worldwide market for autoimmune tests was estimated at
$250M and forecast to grow to $410M by 2010 (Kalorama Information April 2006).
Robert Booth, CEO of Pronostics said: “We are delighted to have partnered with a
leading distributor in the autoimmune diagnostics field. The agreement is an
endorsement of the superiority of our UltraPlex™ technology which underpins our
range of multiplexed diagnostic assays. With this agreement, we can now expand
the benefits of UltraPlex™ into the largest market for diagnostics in Europe’’.
UltraPlex™ is an exceptionally accurate, digital multiplexing solution which
enables tens to hundreds of tests to be performed simultaneously in a single
assay using a microscopic bar-coding system. The company’s lead product, the
UltraPlex™ ANA assay, which consists of 11 tests in one, provides valuable time
and cost savings compared to existing serial testing approaches using panels of
Hep-2 screens and ELISA tests. It allows hospitals and laboratories to perform
fully automated profiles of patient samples and gives both quantitative and
qualitative results for antibodies to autoimmune diseases.
Dr Dirk Roggenbuck, CEO of Medipan, added: “We are very pleased to have been
chosen as the distributor for the UltraPlex™ range of autoimmune assays. The
UltraPlex™ platform is more efficient and economical in the diagnosis of
autoimmune diseases than conventional approaches and we are looking forward to
providing our customers with this improved service.”
-ends-
Notes to editors
About PRONOSTICS
Pronostics is a leading clinical diagnostics company, providing diagnostic and
disease monitoring applications, through its core UltraPlex™ technology.
UltraPlex™ is a ‘next generation’ multiplexing solution enabling tens to
hundreds of assays to be performed simultaneously in a single test using a
microscopic digital bar-coding system. UltraPlex™ improves the speed, efficiency
and cost of clinical diagnostic testing and drug development and combined with
Pronostics’ FingerPrint Immunomics technology, is enabling the next generation
multivariate diagnostics.
Websites: http://www.pro-nostics.com
and http:///www.ultraplex.com
About MEDIPAN
Medipan, founded in 1992 by Reinhold Hartwig and Dr. Horst Steinmaus, is an
accepted and innovative partner for laboratories and physicians inside and
outside of Germany.
Medipan develops and distributes in vitro diagnostic tests, predominantly in the
field of Autoimmunity. Medipan‘s product portfolio provides a wide range of
assays and is expanding continuously. The company offers technical, medical and
scientific expertise and support ensuring the success of their partner’s
clinical and business objectives.
Website: http://www.medipan.de
For further information, please contact:
College Hill:
Tony Stephenson, Claire Mosley, Katja Stout
Phone: +44 20 7457 2020
Email: pronostics@collegehill.com
| |
|
